# **Special Issue**

## **Protein Kinases and Cancer**

## Message from the Guest Editors

During the latter part of the twentieth century, it has continuously been recognized that protein kinases represent a large group of enzymes involved in the phosphorylation of proteins at various sites, thereby altering their functional activities. Because of the vast involvement of protein kinases in cell biological functions and their role in various disease states, it stands to reason that protein kinases have attracted much attention as possible targets for therapeutic intervention. There is a large body of ongoing investigations in this subject area as many different protein kinases are implicated in cancer development and survival. The involvement of protein kinases in cancer is of focal interest because they serve as existing and potential targets for cancer therapy and this is also a highly active area of research. The present Special Issue "Protein Kinases and Cancer" represents a compendium of manuscripts and review articles involving different protein kinases with respect to their biological function in various cancers and their potential as therapeutic targets.

### **Guest Editors**

Prof. Dr. Khalil Ahmed

Minneapolis V.A. Health Care System, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA

### Dr. Janeen Trembley

- 1. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
- 2. Research Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA

## **Deadline for manuscript submissions**

closed (30 April 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/15508

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

